Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years

Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study